Avita MedicalRCEL
Recorded

Avita Medical Investor update

Review the key takeaways and the transcript of this earnings call.

Period 0Duration46 minParticipants4

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Rudi MichelsonInvestor Relations Executive

Good morning, and thank you for joining this AVITA Medical quarterly Australian webinar. I'm Rudi Michelson of Monsoon Communications. The AVITA team, CEO Cary Vance, CFO David O'Toole, and Ben Atkins, VP Investor Relations and Corporate Communications, are in Australia for a Sydney-Melbourne roadshow this week, and this webinar has been arranged so everyone has a chance to be briefed direct and ask questions on AVITA's progress. You can submit questions using the Q&A function, and we'll try to get to them after the presentation. I'll now hand over to Cary Vance to begin the presentation.

Cary VanceCEO

Thank you, Rudy. It's good to be with all of you again. Appreciate your time today. Look forward to updating you on the company. We've been working hard. We've made some progress. I want to harken back to a year ago when I was a few weeks into the job. I came to Australia in November, and we did this webinar and tried to explain where I thought the company was at. I committed to digging in, drilling in commercially and operationally to the business to understand how we can make the improvements that are needed and were needed, and I think we did that. I think in Q4 last year, we stabilized the business. I think we really started to understand the market, our products, how they can impact patients, and how we can create leverage in the marketplace to grow.

Cary VanceCEO

We went on then to make some commitments for 2026 in terms of guidance and committed to growing every quarter, which we've done. Then as we went along throughout the year, and we've grown every quarter and had additional discipline around operations, around cash use, we increased our guidance after Q2. We increased our guidance again after Q3, and we reaffirmed our pledge at the end of Q2 to get to cash flow breakeven and generate cash in Q4. So, it's been a progressive year. A lot of good things happening both on the back end of the business and the front end. So, excited to give you an update of our Q3 numbers today. Again, as I just referenced, when I was here a year ago, we were talking about $17.1 million, $17.6 million as kind of a baseline of the business across our portfolio.

Cary VanceCEO

What we basically did is marched quarter over quarter this year to progressive growth, really across the product lines, even within RECELL across those product lines. Our manual system, as well as RECELL GO and RECELL GO mini, are all being utilized in a greater way, additional physicians using it, and then the physicians using it doing so with different types of procedures, different size procedures. Along with that, as you might expect, we looked at cash use, and we generally have a Q1 set of one-time payments, and that's the $9.9 million there. But other than that, we marched towards cash flow breakeven, and we made a big jump in that regard to going from $3.2 million to $600,000 this past quarter. Again, we reaffirmed that we'll be cash flow breakeven and generate cash in Q4. We raised our guidance to $92 million to $94 million as well.

Cary VanceCEO

One thing I want to point out here, that we're really excited about the $26.1 million quarter, but if you look at those bars on that graph, it's not a particular straight line this year. There's, in a good way, I guess we had a real bump in Q3. My estimation, in speaking to our sales leaders and applying some analytics to it, I believe there's about $1 million of that is just a lot of patients. In the U.S., July and August were very hot months. People are out doing fireworks and barbecues, and it's just hot out there. It created a climate, unfortunately for them, with large wounds and several wounds in patients, and that impacted the revenue, I think, to a $1 million degree.

Cary VanceCEO

When you look at our guidance, $92 million-$94 million, it basically says, well, you're going to do between $24.9 million and $26.9 million. If you look at that upper end of the guidance and you say, "Well, are you saying you're only going to do $26.5 million or something like that at the best?" That's pretty flat to Q3. That's not so much a commentary on Q4 and being flat. It's more a commentary on Q3 being very robust. If you drew a line from $19.3 million to $21.7 million to, let's say, $25 million, and then to nearly $27 million, that's the kind of trajectory organically that the company is on right now that we can count on, and that we can count on going into 2027 as we start to look to continue to grow quarter-over-quarter throughout 2027.

Cary VanceCEO

That kind of seasonality in Q3, we pretty much have an N of one in terms of whether or not that's going to occur every summer in the U.S. We'll see what happens this summer, and as we go along this, we try to be very transparent about understanding our business and the tendencies that the market has in the U.S. so that you can track with that as we do. Again, we're growing across our product lines. In here, you might see a couple flatness, and I'll address that in a second. But really, RECELL quarter-over-quarter was 20% growth, as was Cohealyx. We're real happy with how that's growing. PermeaDerm flatness there, it's not real flatness. It's just that when a product line is so small that it only takes a couple orders to push into October to make it look flat.

Cary VanceCEO

I think you'll see us bounce back here in Q4 with some good growth in PermeaDerm. Same thing with international. Being so small, it doesn't take much to skew that a little bit. Feel really good across the product portfolio in the U.S. and internationally. On the right side, you just see a confirmation it's not just about revenue going up, but units being used from a volumetric standpoint. Just want to share that kind of data so that you see this isn't just a matter of us taking price or any other anomaly in terms of revenue going up, but it's true volume increase quarter-over-quarter. I'll hand it over to David to dive into the numbers a little bit more.

David O'TooleCFO

Thanks, Kerry, and good morning to everyone on the call. Appreciate you taking the time. I want to point out a few things on this slide that may not be apparent. For one, you can see that we're getting to a point where we're getting operating leverage. We had revenue increase of $4.4 million from Q2 of 2026 to Q3 of 2026, and our operating expenses stayed flat. We're generating more revenue, keeping our operating expenses at a constant level, and on top of that, we've increased our gross margin. Our gross margin for RECELL only is at 88.4% in Q3, and there was some dilution because, as everyone knows, we share the ASP, the average sales price, with our two partners for Cohealyx and PermeaDerm at around 50% each. There will continue to be some dilution as those products grow.

David O'TooleCFO

However, we think there's so much opportunity for RECELL at a higher margin that we don't see our gross profit margin going down below the 82%-83%, 84%. You can see that we increased that gross profit margin from Q2 of 2026 to Q3 of 2026 by 210 basis points. We did that through looking at some manufacturing inefficiencies. We took some costs out. We had been working through some obsolescence and reserves that we had in previous quarters. All of that's done. Again, we believe that our gross margin for RECELL will continue in the 85%-89%, and gross profit margin overall disclosed will be in the 82%-84%. Kerry's talked about the use of cash going down. Our expectation is that we're going to cross over this quarter to cash flow break-even and start generating cash.

David O'TooleCFO

We do, as was pointed out earlier, and I'll just state it also, we do believe that in first quarter of 2027, we have these one-time payments that benefits reset. We have incentive compensation that we have to pay, bonuses, commissions, and also we've had this payment to Regenity, our partner for Cohealyx, on the books of $3 million that will need to be paid in January. So you will see a use of cash in the first quarter of 2027 again, and it won't be to the magnitude of the $9.9 million that we had this year, but it will be a use of cash, and then we expect every quarter thereafter to be generating cash. Our revenue will be such going out of 2027 that we should not see a use of cash in the first quarter of 2028 and going forward.

David O'TooleCFO

We believe that we will get to cash flow break-even this quarter, have use of cash next quarter, in first quarter of 2027, and then be generating cash thereafter. One last thing I want to talk about is we did draw down, we had this debt facility with Perceptive Advisors, and it was a total debt facility of $60 million. We had already drawn down $50, and the remaining $10 was only available if we had reached $85 million trailing 12 months revenue, and we did that this quarter, and we did that probably two quarters before even Perceptive thought we were going to do that, because that $85 million was available through March of 2027. So it was available. It was a short-term way to put cash on our balance sheet.

David O'TooleCFO

We now have pro forma of about $21 million of cash. It also allowed us, and this is probably just a U.S. concept, but in our financial reporting to the SEC, we had previous quarters had a qualification around substantial doubt about our ability to continue as a going concern. We were able to alleviate that qualification, and that will no longer be in our financial reporting going forward.

Cary VanceCEO

Next slide. Let me just jump in if I could, David, to talk about operating expense, because over the last few days in meetings, we have been asked about our ability to keep this relatively flat over the next one, two, three years.

Cary VanceCEO

I think some of you have been in with AVITA for a while, and when I took over last November again, or last October, one of the complaints that I had heard is how much money we spend, right? Some of that was getting a handle on some of our operational expenses, and that is David and his team and everybody at the company did a great job of that.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day